Tonix Pharmaceuticals Reports Third Quarter 2014 Financial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Tonix Pharmaceuticals Reports Third Quarter 2014 Financial Results

NEW YORK, Nov. 10, 2014 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP ) announced its financial results for the quarter ended September 30, 2014.

"In September, we announced preliminary top line results from the Phase 2b BESTFIT study of TNX-102 SL in fibromyalgia. We view TNX-102 SL as a broadly active and well tolerated therapeutic candidate for fibromyalgia, and we look forward to initiating a Phase 3 registration program in the first half of 2015 following communication with the FDA," said Seth Lederman, M.D., president and chief executive officer. "We expect to announce the start of our Phase 2 AtEase study of TNX-102 SL in post-traumatic stress disorder in the coming weeks. Also, we plan to advance our third clinical program, TNX-201 for episodic tension-type headache, into a Phase 2 trial in the first half of next year."

Third Quarter Financial Results

For the three months ended September 30, 2014, Tonix reported a net loss of $7.4 million, or $0.71 per share, as compared to a net loss of $3.1 million, or $0.87 per share, for the third quarter of 2013. The increase in net loss is primarily due to an increase in research and development expense. At September 30, 2014, Tonix's cash totaled $46.2 million as compared to $8.2 million at December 31, 2013.

About Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals is a clinical-stage company developing first-in-class medicines for common disorders of the central nervous system, including fibromyalgia, post-traumatic stress disorder (PTSD), and episodic tension-type headache. These disorders are characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and significant economic burden. Tonix's lead candidate, TNX-102 SL, is intended to be a first-line treatment for fibromyalgia and for PTSD. A Phase 2b trial of TNX-102 SL in fibromyalgia (BESTFIT) has been completed with an optimal therapeutic dose identified, and Tonix is preparing to initiate a Phase 3 program to support registration. A Phase 2 trial of TNX-102 SL in PTSD (AtEase) is expected to begin in the fourth quarter of 2014. TNX-201 is in development for episodic tension-type headache and is currently being evaluated in a Phase 1 trial. To learn more, please visit www.tonixpharma.com .

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate" and "intend," among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K filed with the SEC on March 28, 2014 and future periodic reports filed with the Securities and Exchange Commission. All of the Company's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date hereof.

TONIX PHARMACEUTICALS HOLDING CORP.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
(Unaudited)
         
  Three Months Ended Nine Months Ended
  September 30, September 30,
  2014 2013 2014 2013
Costs and expenses:        
Research and development $5,217 1,637 12,842 3,322
General and administrative 2,217 1,455 5,810 3,857
Total operating expenses 7,434 3,092 18,652 7,179
         
Operating loss  (7,434)  (3,092)  (18,652)  (7,179)
Interest and other financing costs, net 15 2 25 2
Net loss  $ (7,419)  (3,090)  (18,627)  (7,177)
Net loss per common share - basic and diluted  $ (0.71)  (0.87)  (1.92)  (2.73)
Weighted average common shares outstanding - basic and diluted 10,497 3,537 9,719 2,633
 
TONIX PHARMACEUTICALS HOLDING CORP.
CONDENSED CONSOLIDATED BALANCE SHEET DATA
(in thousands)
(Unaudited)
  September 30, December 31,
  2014 2013 (1)
Assets    
Cash $46,227 8,202
Prepaid expenses and other current assets 699 429
Total current assets 46,926 8,631
Other non-current assets 402 105
Total assets $47,328 8,736
     
Liabilities and stockholders' equity    
Total liabilities $3,551 2,224
Stockholders' equity 43,777 6,512
Total liabilities and stockholders' equity $47,328 8,736

(1) The condensed consolidated balance sheet for the year ended December 31, 2013 has been derived from the audited financial statements but does not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.

Tonix Pharmaceuticals Holding Corp: Leland Gershell, M.D., Ph.D. Chief Financial Officer (212) 980-9155 x104 Investor Relations Martini Communications LLC Amy Martini Public Relations: Dian Griesel Int'l. Susan Forman / Laura Radocaj (212) 825-3210

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Circuit Adds Gabe Klein as Microtransit Expansion Adviser

Updated Category News Views 29

Municipal mobility is a slow, political grind, not a shiny-app contest, and Circuit’s decision to add Gabe Klein to its board looks aimed squarely at that reality. The all-electric microtransit operator has brought aboard somebody who has worked inside the machinery of city government, federal transportation policy, electrification, venture investing, and transportation...

Continue Reading
Exiger's CEO Honored for Military Support Excellence

Updated Category News Views 256

Recognizing Civilian and Military Leadership When you hear "recognition in the military sector," it isn't just a pat on the back. It's a whole parade of brass hats and high-flyers giving their nods. So, November 10th wasn't just any regular day—Brandon Daniels, CEO of Exiger, gets a shiny, prestigious Five-Star Award for his "extraordinary support" of our military...

Continue Reading
Breakthrough T1D Gala Puts Research Progress First

Updated Category News Views 5

One person living without insulin after a cell-therapy trial is the detail that cuts through all the ballroom polish tonight. Breakthrough T1D's 53rd Annual New York City Promise Gala lands at the Plaza Hotel during National Diabetes Awareness Month, and it carries a message worth handling carefully: research can produce extraordinary outcomes, but one participant's...

Continue Reading
LRM Adds Two IND Studies Testing Injectable PDGF in Skin

Updated Category News Views 14

Under-eye medicine has a nasty habit of outrunning the evidence, which makes LRM's decision to put injectable rhPDGF-BB through more formal study worth watching. Lynch Regenerative Medicine has announced two FDA-accepted INDs for investigator-initiated clinical trials: one examining what the material does inside facial skin, the other testing it for infraorbital...

Continue Reading
COPD Support Program Targets a Costly Care Gap Today

Updated Category News Views 129

Breathing trouble gets shrugged off far too easily, and that casual mistake has consequences. World COPD Day puts chronic obstructive pulmonary disease back in view, with the American Lung Association emphasizing a free Lung Health Navigator program for people living with COPD, their caregivers and families. This is not flashy medicine or a miracle-cure pitch. It is...

Continue Reading
Historic China-Russia-US Summit Aims for Global Stability

Updated Category News Views 91

The Weight of History in Shenzhen When the big players decide to talk face-to-face, it's more than just a photo op. This week in Shenzhen, the leaders of China, Russia, and the United States are doing just that. And let me tell you, it's the kind of gathering that can either stabilize the gears of global politics or grease the wheels of tension. This chinwag isn't just...

Continue Reading
Anycubic Pushes Toward a Smoother 3D Printing Ecosystem

Updated Category News Views 51

Friction Is the Enemy in Consumer 3D Printing A printer that makes a beautiful object only after three failed attempts is not a consumer product; it is a weekend argument with plastic. That is the useful lens for Anycubic's Formnext 2026 showing in Frankfurt on November 18. The company is not merely rolling out FDM and resin machines at Booth F01 in Hall 12.0. It is...

Continue Reading
Oracle Takes AI to Construction's Messy Project Middle

Updated Category News Views 157

A stalled drywall inspection can wreck a schedule faster than any glossy AI pitch can repair it. That is the grimy, practical corner Oracle is aiming at with its latest Oracle Primavera Cloud upgrades: the daily hunt for answers, the repeated logging of familiar risks, and the finger-pointing that starts when a milestone is suddenly in danger. This is not a chatbot being...

Continue Reading
Abacus Global Faces Scrutiny Over Accounting Practices

Updated Category News Views 265

Storm Clouds Gather over Abacus Global Management If it ain't one thing, it's another—at least that's what folks holding the bag with Abacus Global (ABX) are thinking right now. News of a pending investigation has dropped like a lead balloon, and the air is thick with scrutiny over their financial dealings. We're jawing about related-party transactions now under the...

Continue Reading
Ampace Fire Test Gives Data Centers Useful Evidence

Updated Category News Views 134

Battery cabinets are becoming the awkward guest in the AI data-center boom: absolutely necessary, expensive to install, and nobody wants to discover their failure behavior during a real emergency. Ampace’s newly presented PU100 large-scale fire-test results deserve attention for that reason. This is not a magic safety stamp, and the company says the findings apply only...

Continue Reading

Top 5 Most Recently Viewed Articles

Jøtul Group's Financial Challenges and Strategic Response

Updated Category News Views 138

Understanding the Jøtul Group's Financial Landscape The Jøtul Group is a major player in the fireplace market, known for its exceptional range of products that cater to various consumer preferences. Founded in 1853, this company proudly represents some of Europe's most reputable brands, including Jøtul, Scan, and Ravelli. Each brand encapsulates a unique design...

Continue Reading
Capri Holdings Limited Faces Legal Scrutiny: What You Need to Know

Updated Category News Views 425

Capri Holdings Limited Under Investigation Capri Holdings Limited, known for its involvement in the luxury fashion sector, has recently come under the spotlight due to an ongoing investigation. This investigation is being led by the Law Offices of Howard G. Smith on behalf of the investors of the company. The core of the inquiry centers around potential violations of...

Continue Reading
eBay's Year-End Performance and 2025 Outlook Highlights

Updated Category News Views 1606

eBay Inc. Financial Performance Overview eBay Inc. has showcased remarkable financial growth in its latest performance report. The company announced substantial revenue figures and gross merchandise volume (GMV) for the last quarter and the full year, reinforcing its position as a leading global commerce platform. Key Financial Highlights of Q4 eBay's revenue reached an...

Continue Reading
Join Us for a Free Webinar on Stepfamily Support Strategies

Updated Category News Views 183

Understanding Stepfamily Dynamics Navigating the complexities of blended families can be challenging, and that is exactly why this free webinar, titled From Conflict to Connection: Navigating Stepfamily Dynamics, offers unparalleled insights for parents and stepparents alike. The event is set to feature expert panelists who specialize in co-parenting and stepfamily...

Continue Reading
Lamb Weston Faces Sharp Decline Amid Nasdaq Rally in Stocks

Updated Category News Views 143

Nasdaq Composite Shows Robust Gains The U.S. stock market experienced a positive trajectory as the Nasdaq Composite surged over 1% on a recent trading day. Investors found motivation in the optimistic outlook surrounding technology shares, which rose by 1.6%. Dow and S&P 500 Performance The Dow Jones Industrial Average reflected a modest uptick of 0.55%, reaching an...

Continue Reading